March 28, 2023
|
Posted by admin
Dozens of clinical trials are testing mRNA treatment vaccines in people with various types of cancer, including pancreatic cancer, colorectal cancer, and melanoma. Some vaccines are being evaluated in combination with drugs that enhance the body’s immune response to tumors. But no mRNA cancer vaccine has been approved by the US Food and Drug Administration for use either alone or with other cancer treatments.
“mRNA vaccine technology is extremely promising for infectious diseases and may lead to new kinds of vaccines,” said Elad Sharon, M.D., M.P.H., of NCI‘s Division of Cancer Treatment and Diagnosis. “For other applications, such as the treatment of cancer, research on mRNA vaccines also appears promising, but these approaches have not yet proven themselves.”
With findings starting to emerge from ongoing clinical trials of mRNA cancer vaccines, researchers could soon learn more about the safety and effectiveness of these treatments, Dr. Sharon added. Over the past 30 years, researchers have learned how to engineer stable forms of mRNA and deliver these molecules to the body through vaccines. Once in the body, the mRNA instructs cells that take up the vaccine to produce proteins that may stimulate an immune response against these same proteins when they are present in intact viruses or tumor cells. Among the cells likely to take up mRNA from a vaccine are dendritic cells, which are the sentinels of the immune system. After taking up and translating the mRNA, dendritic cells present the resulting proteins, or antigens, to immune cells such as T cells, starting the immune response.
“Dendritic cells act as teachers, educating T cells so that they can search for and kill cancer cells or virus-infected cells,” depending on the antigen, said Karine Breckpot, Ph.D., of the Vrije Universiteit Brussel in Belgium, who studies mRNA vaccines. The mRNA included in the Pfizer-BioNTech and the Moderna coronavirus vaccines instructs cells to produce a version of the “spike” protein that studs the surface of SARS-CoV-2. The immune system sees the spike protein presented by the dendritic cells as foreign and mobilizes some immune cells to produce antibodies and other immune cells to fight off the apparent infection. Having been exposed to the spike protein free of the virus, the immune system is now prepared, or primed, to react strongly to a subsequent infection with the actual SARS-CoV-2 virus.
Source: https://www.cancer.gov/
Categories: Uncategorized
| 
Tags: antibodies, antigens, cancer, cells, colorectal cancer, Dendritic cells, drugs, Food and Drug Administration, immune response, melanoma, Moderna, mRNA, NCI, pancreatic cancer, Pfizer-BioNTech, proteins, SARS-CoV-2 virus, spike protein, T-cells, tumor, tumors, vaccines, Vrije Universiteit Brussel
March 23, 2023
|
Posted by admin
Terminal leukaemia patients who were not responding to treatment now have hope for a cure, thanks to a new experimental pill called revumenib. This drug has completely eliminated cancer in a third of the participants in a long-awaited clinical trial in the United States. Although not all patients showed complete remission, scientists remain hopeful as the results indicate that the pill might pave the way to a cure for leukaemia in the future.
“We’re incredibly hopeful by these results of patients that received this drug. This was their last chance,” said study co-author Dr Ghayas Issa, a leukaemia physician at the MD Anderson Cancer Center at the University of Texas. “They have progressed on multiple lines of therapy and a fraction of them, about half, had disappearance of their leukaemia cells from their bone marrow,” he told Euronews Next.
Acute myeloid leukaemia (AML) is a type of cancer that attacks the bone marrow, where blood cells are produced, and causes the uncontrolled production of defective cells. Revumenib is a new class of targeted therapy for acute leukaemia that inhibits a specific protein called menin. The drug works by reprogramming leukaemia cells back into normal cells. Menin is involved in the complex machinery that gets hijacked by leukaemia cells and causes normal blood cells to turn into cancerous ones. By using revumenib, Issa explained, the engine is turned off and leukaemia cells are turned back into normal cells, resulting in remission.
This formula has already saved 18 lives as part of the clinical trial, whose promising results were published this month in Nature. The preliminary results showed that 53 per cent of patients responded to revumenib, and 30 per cent had a complete remission with no cancer detectable in their blood. Based on the data from this trial, in December 2022 the US Food and Drug Administration granted revumenib “breakthrough therapy designation” to help fast-track its development and regulatory review.
“This is definitely a breakthrough and it’s a result of years of science. A lot of groups had worked hard in the lab to understand what is causing these leukaemias,” Issa said. However, he explained that the drug does not work for all patients. It is for a specific subset of leukaemias that generally have missing or mislabeled genes or a chromosome fusion. The experimental pill targets the most common mutation in acute myeloid leukaemia, a gene called NPM1, and a less common fusion called KMT2A. Combined, these mutations are estimated to occur in about 30 to 40 per cent of people with acute myeloid leukaemia.
The phase 1 trial enrolled 68 patients at nine US hospitals. All of them had seen their leukaemia return after other treatments or had never responded well to traditional chemotherapy drugs in the first place.
Source: https://www.euronews.com/next/
Categories: Uncategorized
| Tags: Acute myeloid leukaemia, AML, bone marrow, cancer, cells, drug, Food and Drug Administratio, gene, KMT2A, leukaemia, Menin, NPM1, pill, protein, remission, revumenib, University of Texas
February 28, 2023
|
Posted by admin
A new highly accurate blood test for prostate cancer is giving doctors hope that they will soon be able to screen for the disease. Almost one in eight men in Britain will develop prostate cancer in their lives, and the disease claims 12,000 lives a year – as many as breast cancer. Yet no screening programme exists because the current method, the prostate-specific antigen (PSA) test, is notoriously unreliable – missing cancers and resulting in many ‘false positives’.
Now scientists say they have robust results from a study of nearly 1,000 men, showing a new test which looks for prostate cancer cells in the blood is highly accurate. Last night, experts said the ‘Trublood’ test offered ‘great promise’ to improve early detection of the disease.
British medics have been working to evaluate the test, developed by Indian firm Datar Cancer Genetics. Results of the study, seeing how well it can spot cancer in 960 men – of whom 160 were known to have prostate cancer – have proven highly encouraging. It correctly spotted all 160 with the disease, without mis-identifying any of the 800 healthy men as having it.
Researchers in India collaborated with Imperial College and Guy’s Hospital in London on the study, which is published in the journal Cancer Medicine.
‘These results show great promise and suggest that it may be possible to use this test to detect the cancer in the first place,’ said Prostate Cancer UK.
Source: https://phys.org/
Categories: Uncategorized
| Tags: blood test, breast cancer, cells, Datar Cancer Genetics, Guy’s Hospital in London, Imperial College, prostate cancer, prostate-specific antigen, PSA, Trublood
February 22, 2023
|
Posted by admin
Messenger RNA (mRNA) vaccines may be the hottest thing in science now, as they helped turn the tide against COVID-19. But even before the pandemic began, Memorial Sloan Kettering Cancer Center researchers had already been working to use mRNA vaccine technology to treat cancer. Vinod Balachandran a physician-scientist affiliated with the David M. Rubenstein Center for Pancreatic Cancer Research and the Parker Institute for Cancer Immunotherapy, is leading the only clinical trial to test mRNA vaccines for pancreatic cancer. The key to these vaccines appears to be proteins in the pancreatic tumors, called neoantigens, which alert the immune system to keep the cancer at bay.
The vaccines are custom-made for every person. The hope is that the vaccine will stimulate the production of certain immune cells, called T cells, that recognize pancreatic cancer cells. This could reduce the risk of the cancer returning after the main tumor was removed by surgery. In 8 of 16 patients studied, the vaccines activated T cells that recognize the patient’s own pancreatic cancers. These patients also showed delayed recurrence of their pancreatic cancers, suggesting the T cells activated by the vaccines may be having the desired effect to keep pancreatic cancers in check.
There has been great interest in using immunotherapy for pancreatic cancer because nothing else has worked very well. We thought immunotherapy held promise because of research we began about seven years ago. A small subset of patients with pancreatic cancer manage to beat the odds and survive after their tumor is removed. We looked at the tumors taken from these select patients and saw that the tumors had an especially large number of immune cells in them, especially T cells. Something in the tumor cells seemed to be sending out a signal that alerted the T cells and drew them in.
Source: https://www.thebrighterside.news/
Categories: Uncategorized
| Tags: cancer, cells, COVID-19, David M. Rubenstein Center for Pancreatic Cancer Research, immune cells, immune system, immunotherapy, Memorial Sloan Kettering Cancer Center, messenger RNA, mRNA, neoantigens, pancreatic cancer, pancreatic tumors, Parker Institute for Cancer Immunotherapy, proteins, T-cells, vaccines
February 16, 2023
|
Posted by admin
At 82 years old, with an aggressive form of blood cancer that six courses of chemotherapy had failed to eliminate, “Paul” appeared to be out of options. With each long and unpleasant round of treatment, his doctors had been working their way down a list of common cancer drugs, hoping to hit on something that would prove effective—and crossing them off one by one. The usual cancer killers were not doing their job.
With nothing to lose, Paul’s doctors enrolled him in a trial set up by the Medical University of Vienna in Austria, where he lives. The university was testing a new matchmaking technology developed by a UK-based company called Exscientia that pairs individual patients with the precise drugs they need, taking into account the subtle biological differences between people.
The researchers took a small sample of tissue from Paul (his real name is not known because his identity was obscured in the trial). They divided the sample, which included both normal cells and cancer cells, into more than a hundred pieces and exposed them to various cocktails of drugs. Then, using robotic automation and computer vision (machine-learning models trained to identify small changes in cells), they watched to see what would happen. In effect, the researchers were doing what the doctors had done: trying different drugs to see what worked. But instead of putting a patient through multiple months-long courses of chemotherapy, they were testing dozens of treatments all at the same time.
The approach allowed the team to carry out an exhaustive search for the right drug. Some of the medicines didn’t kill Paul’s cancer cells. Others harmed his healthy cells. Paul was too frail to take the drug that came out on top. So he was given the runner-up in the matchmaking process: a cancer drug marketed by the pharma giant Johnson & Johnson that Paul’s doctors had not tried because previous trials had suggested it was not effective at treating his type of cancer.
It worked. Two years on, Paul was in complete remission—his cancer was gone. The approach is a big change for the treatment of cancer, says Exscientia’s CEO, Andrew Hopkins: “The technology we have to test drugs in the clinic really does translate to real patients.”
Source: https://www.technologyreview.com/
Categories: Uncategorized
| Tags: AI, Artificial Intelligence, cancer cells, cells, chemotherapy, complete remission, drugs, Exscientia, Johnson & Johnson, machine-learning, matchmaking technology, Medical University of Vienna, robotic automation, tissue
February 14, 2023
|
Posted by admin
Retinal cells grown from stem cells can reach out and connect with neighbors, according to a new study, completing a “handshake” that may show the cells are ready for trials in humans with degenerative eye disorders. Over a decade ago, researchers from the University of Wisconsin–Madison (UW-Madison) developed a way to grow organized clusters of cells, called organoids, that resemble the retina, the light-sensitive tissue at the back of the eye. They coaxed human skin cells reprogrammed to act as stem cells to develop into layers of several types of retinal cells that sense light and ultimately transmit what we see to the brain.
“We wanted to use the cells from those organoids as replacement parts for the same types of cells that have been lost in the course of retinal diseases,” says David Gamm, the UW–Madison ophthalmology professor and director of the McPherson Eye Research Institute whose lab developed the organoids. “But after being grown in a laboratory dish for months as compact clusters, the question remained — will the cells behave appropriately after we tease them apart? Because that is key to introducing them into a patient’s eye.”
During 2022, Gamm and UW–Madison collaborators published studies showing that dish-grown retinal cells called photoreceptors respond like those in a healthy retina to different wavelengths and intensities of light, and that once they are separated from adjacent cells in their organoid, they can reach out toward new neighbors with characteristic biological cords called axons.
“The last piece of the puzzle was to see if these cords had the ability to plug into, or shake hands with, other retinal cell types in order to communicate,” says Gamm, whose new results on successful connections between the cells will be published this week in the Proceedings of the National Academy of Sciences. Cells in the retina and brain communicate across synapses, tiny gaps at the tips of their cords. To confirm that their lab-grown retinal cells have the capacity to replace diseased cells and carry sensory information like healthy ones, the researchers needed to show that they could make synapses.
Source: https://news.wisc.edu/
AND
https://www.thebrighterside.news/
Categories: Uncategorized
| Tags: axons, biological cords, blindness, brain, cells, degenerative eye disorders, light, organoids, photoreceptors, retina, Retinal cells, synapse, University of Wisconsin-Madison, UW-Madison
February 6, 2023
|
Posted by admin
Genes that trigger cancer could be turned off - before people are even born, according to new research. Scientists have found a tumour 'switch' that develops hours after fertilisation. The discovery offers hope of a screening program, personalised vaccines - or even embryo engineering.
"Our work could open a new clinical chapter for the early detection of cancer," sait Co author Professor Tony Perry, of the University of Bath.
In experiments on mice, the international team found gene activity in embryos kicks off within four hours of sperm injection. These include 'oncogenes' which have the potential to cause cancer - if mutated. The findings are expected to apply to humans. "Many factors responsible for the dawn of gene activity in embryos have long been known to be major oncogenes," explained Prof Perry. It is the first time a pre-set order of events has been established in one-cell embryos in any species.
When an embryo is formed, its genes – donated by a fertilising sperm and egg – are silent. Somehow, at an early stage of development, embryo genes must be switched on. Without this vital 'genes on' switch in the embryo, none of us would be here, yet surprisingly little is known about what the switch looks like, or the identity of the 'molecular finger' that pushes the switch.
You must be logged in to view this content.
Categories: Uncategorized
| Tags: birth, cancer, cells, egg, embryo engineering, embryologists, embryos, genes, messenger RNA, molecular finger, mRNA, mutation, oncogenes, proteins, sequencing, sperm, switch, tumour 'switch', University of Bath, University of Cambridge
January 23, 2023
|
Posted by admin
A team of researchers led by The University of Texas MD Anderson Cancer Center has developed a novel delivery system for messenger RNA (mRNA) using extracellular vesicles (EVs). The new technique has the potential to overcome many of the delivery hurdles faced by other promising mRNA therapies.
In the study, published today in Nature Biomedical Engineering, the researchers use EV-encapsulated mRNA to initiate and sustain collagen production for several months in the cells of photoaged skin in laboratory models. It is the first therapy to demonstrate this ability and represents a proof-of-concept for deploying the EV mRNA therapy.
“This is an entirely new modality for delivering mRNA,” said corresponding author Betty Kim, M.D., Ph.D., professor of Neurosurgery. “We used it in our study to initiate collagen production in cells, but it has the potential to be a delivery system for a number of mRNA therapies that currently have no good method for being delivered.”
The genetic code for building specific proteins is contained in mRNA but delivering mRNA within the body is one of the largest hurdles facing clinical applications of many mRNA-based therapies. The current COVID-19 vaccines, which marked the first widespread use of mRNA therapy, use lipid nanoparticles for delivery, and the other primary delivery systems for genetic materials so far have been viral based. However, each of these approaches comes with certain limitations and challenges.
Extracellular vesicles are small structures created by cells that transport biomolecules and nucleic acids in the body. These naturally occurring particles can be modified to carry mRNAs, which gives them the benefit of innate biocompatibility without triggering a strong immune response, allowing them to be administered multiple times. Additionally, their size allows them to carry even the largest human genes and proteins.
You must be logged in to view this content.
Categories: Uncategorized
| Tags: biomolecules, cells, COL1A1 mRNA, collagen, collagen production, ev, extracellular vesicles, genetic, immune response, lipid nanoparticles, messenger RNA, mRNA, nucleic acids, photoaged skin, proteins, University of Texas MD Anderson Cancer Center, WRINKLES
January 16, 2023
|
Posted by admin
The best Band-Aids could be sprouting from your scalp, a new study suggests. British researchers say hair follicles may have wound-healing properties, with the potential to avoid lifelong scars that can be damaging to one’s confidence.
The study out of Imperial College London reports that scars treated with hair follicle transplants began to act similarly to uninjured skin, generating new cells, blood vessels, gene expression, and even restoring itself through collagen.
“Around 100 million people per year acquire scars in high-income countries alone, primarily as a result of surgeries. The global incidence of scars is much higher and includes extensive scarring formed after burn and traumatic injuries. Our work opens new avenues for treating scars and could even change our approach to preventing them,” says Dr Francisco Jiménez, lead hair transplant surgeon at the Mediteknia Clinic and Associate Research Professor at University Fernando Pessoa Canarias, in Gran Canaria, Spain, in a statement.
Scar tissue in the skin lacks hair, sweat glands, blood vessels and nerves, which are all needed for proper regulation of body temperature, as well as pain and overall sensory detection. Scarring can also disrupt movement ability, thus inducing stress and discomfort for someone.
You must be logged in to view this content.
Categories: Uncategorized
| Tags: : Blood vessels, cell, cells, collagen, follicules, gene expression, hair, hair transplants, Imperial College London, Mediteknia Clinic, nerves, normotrophic scars, pain, scalp, scars, sensory detection, skin, sweat glands, temperature, transplants, University Fernando Pessoa Canarias, wounds
January 4, 2023
|
Posted by admin
New research in the journal Nature Aging takes a page from the field of renewable energy and shows that genetically engineered mitochondria can convert light energy into chemical energy that cells can use, ultimately extending the life of the roundworm C. elegans. While the prospect of sunlight-charged cells in humans is more science fiction than science, the findings shed light on important mechanisms in the aging process.
Caenorhabditis elegans (C. elegans) has been the source of major discoveries in molecular and cell biology
“We know that mitochondrial dysfunction is a consequence of aging,” said Andrew Wojtovich, Ph.D., associate professor of Pharmacology & Physiology at the University of Rochester Medical Center and senior author of the study. “This study found that simply boosting metabolism using light-powered mitochondria gave laboratory worms longer, healthier lives. These findings and new research tools will enable us to further study mitochondria and identify new ways to treat age-related diseases and age healthier.”
Mitochondria are organelles found in most cells in the body. Often referred to as cellular power plants, mitochondria use glucose to produce adenosine triphosphate (ATP), the compound that provides energy for key functions in the cell, such as muscle contraction and the electrical impulses that help nerve cells communicate with each other.
You must be logged in to view this content.
Categories: Uncategorized
| Tags: adenosine triphosphate, aging, ATP, cells, cellular power plants, genetically engineered, light energy, membrane, membrane potential, mitochondria, muscle contraction, nerve cells, organelles, protons, renewable energy, solar panels, University of Rochester Medical Center
Recent Comments